169 related articles for article (PubMed ID: 37592303)
1. The tight junction protein claudin 6 is a potential target for patient-individualized treatment in esophageal and gastric adenocarcinoma and is associated with poor prognosis.
Simon AG; Lyu SI; Laible M; Wöll S; Türeci Ö; Şahin U; Alakus H; Fahrig L; Zander T; Buettner R; Bruns CJ; Schroeder W; Gebauer F; Quaas A
J Transl Med; 2023 Aug; 21(1):552. PubMed ID: 37592303
[TBL] [Abstract][Full Text] [Related]
2. Claudin-6 is a single prognostic marker and functions as a tumor-promoting gene in a subgroup of intestinal type gastric cancer.
Kohmoto T; Masuda K; Shoda K; Takahashi R; Ujiro S; Tange S; Ichikawa D; Otsuji E; Imoto I
Gastric Cancer; 2020 May; 23(3):403-417. PubMed ID: 31654186
[TBL] [Abstract][Full Text] [Related]
3. Chromosomally Unstable Gastric Cancers Overexpressing Claudin-6 Disclose Cross-Talk between HNF1A and HNF4A, and Upregulated Cholesterol Metabolism.
Dwivedi S; Hernández-Montes G; Montaño LF; Rendón-Huerta EP
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430456
[TBL] [Abstract][Full Text] [Related]
4. Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma.
Salem ME; Puccini A; Xiu J; Raghavan D; Lenz HJ; Korn WM; Shields AF; Philip PA; Marshall JL; Goldberg RM
Oncologist; 2018 Nov; 23(11):1319-1327. PubMed ID: 29866946
[TBL] [Abstract][Full Text] [Related]
5. Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer.
Micke P; Mattsson JS; Edlund K; Lohr M; Jirström K; Berglund A; Botling J; Rahnenfuehrer J; Marincevic M; Pontén F; Ekman S; Hengstler J; Wöll S; Sahin U; Türeci O
Int J Cancer; 2014 Nov; 135(9):2206-14. PubMed ID: 24710653
[TBL] [Abstract][Full Text] [Related]
6. Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry.
Alvarez-Manceñido F; Jimenez-Fonseca P; Carmona-Bayonas A; Arrazubi V; Hernandez R; Cano JM; Custodio A; Pericay Pijaume C; Aguado G; Martínez Lago N; Sánchez Cánovas M; Cacho Lavin D; Visa L; Martinez-Torron A; Arias-Martinez A; López F; Limón ML; Vidal Tocino R; Fernández Montes A; Alsina M; Pimentel P; Reguera P; Martín Carnicero A; Ramchandani A; Granja M; Azkarate A; Martín Richard M; Serra O; Hernández Pérez C; Hurtado A; Gil-Negrete A; Sauri T; Morales Del Burgo P; Gallego J
Gastric Cancer; 2021 Jul; 24(4):926-936. PubMed ID: 33651195
[TBL] [Abstract][Full Text] [Related]
7. Aberrant expression of claudin-6 contributes to malignant potentials and drug resistance of cervical adenocarcinoma.
Ito Y; Takasawa A; Takasawa K; Murakami T; Akimoto T; Kyuno D; Kawata Y; Shano K; Kirisawa K; Ota M; Aoyama T; Murata M; Sugimoto K; Chiba H; Saito T; Osanai M
Cancer Sci; 2022 Apr; 113(4):1519-1530. PubMed ID: 35100472
[TBL] [Abstract][Full Text] [Related]
8. Effects of the Tight Junction Protein CLDN6 on Cell Migration and Invasion in High-Grade Meningioma.
Yang A; Yang X; Wang J; Wang X; Wu H; Fan L; Li H; Li J
World Neurosurg; 2021 Jul; 151():e208-e216. PubMed ID: 33862296
[TBL] [Abstract][Full Text] [Related]
9. CLDN6 promotes tumor progression through the YAP1-snail1 axis in gastric cancer.
Yu S; Zhang Y; Li Q; Zhang Z; Zhao G; Xu J
Cell Death Dis; 2019 Dec; 10(12):949. PubMed ID: 31827075
[TBL] [Abstract][Full Text] [Related]
10. Identification of Claudin-6 as a Molecular Biomarker in Pan-Cancer Through Multiple Omics Integrative Analysis.
Zhang C; Guo C; Li Y; Liu K; Zhao Q; Ouyang L
Front Cell Dev Biol; 2021; 9():726656. PubMed ID: 34409042
[TBL] [Abstract][Full Text] [Related]
11. Tight Junction-Related CLDN5 and CLDN6 Genes, and Gap Junction-Related GJB6 and GJB7 Genes Are Somatically Mutated in Gastric and Colorectal Cancers.
Son HJ; An CH; Yoo NJ; Lee SH
Pathol Oncol Res; 2020 Jul; 26(3):1983-1987. PubMed ID: 32170581
[TBL] [Abstract][Full Text] [Related]
12. Phenotypic immune characterization of gastric and esophageal adenocarcinomas reveals profound immune suppression in esophageal tumor locations.
Groen-van Schooten TS; Harrasser M; Seidel J; Bos EN; Fleitas T; van Mourik M; Pouw RE; Goedegebuure RSA; Doeve BH; Sanders J; Bos J; van Berge Henegouwen MI; Thijssen VLJL; van Grieken NCT; van Laarhoven HWM; de Gruijl TD; Derks S
Front Immunol; 2024; 15():1372272. PubMed ID: 38638445
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Significance of Aberrant Claudin-6 Expression in Endometrial Cancer.
Kojima M; Sugimoto K; Tanaka M; Endo Y; Kato H; Honda T; Furukawa S; Nishiyama H; Watanabe T; Soeda S; Fujimori K; Chiba H
Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 32987797
[TBL] [Abstract][Full Text] [Related]
14. Comparing treatment and outcomes in advanced esophageal, gastroesophageal junction, and gastric adenocarcinomas: a population-based study.
Pape M; Vissers PAJ; Dijksterhuis WPM; Bertwistle D; McDonald L; Mostert B; Derks S; Oving IM; Verhoeven RHA; van Laarhoven HWM
Ther Adv Med Oncol; 2023; 15():17588359231162576. PubMed ID: 36970109
[TBL] [Abstract][Full Text] [Related]
15. Prediction of tissue origin of adenocarcinomas in the esophagogastric junction by DNA methylation.
Zhang CD; Takeshima H; Sekine S; Yamashita S; Liu YY; Hattori N; Abe H; Yamashita H; Fukuda M; Imamura Y; Ushiku T; Katai H; Makino H; Watanabe M; Seto Y; Ushijima T
Gastric Cancer; 2022 Mar; 25(2):336-345. PubMed ID: 34557982
[TBL] [Abstract][Full Text] [Related]
16. Bioinformatic analysis reveals potential properties of human Claudin-6 regulation and functions.
Lin D; Guo Y; Li Y; Ruan Y; Zhang M; Jin X; Yang M; Lu Y; Song P; Zhao S; Dong B; Xie Y; Dang Q; Quan C
Oncol Rep; 2017 Aug; 38(2):875-885. PubMed ID: 28656265
[TBL] [Abstract][Full Text] [Related]
17. Association of CLDN6 and CLDN10 With Immune Microenvironment in Ovarian Cancer: A Study of the Claudin Family.
Gao P; Peng T; Cao C; Lin S; Wu P; Huang X; Wei J; Xi L; Yang Q; Wu P
Front Genet; 2021; 12():595436. PubMed ID: 34249076
[TBL] [Abstract][Full Text] [Related]
18. Claudin-6 enhances the malignant progression of gestational trophoblastic neoplasm by promoting proliferation and metastasis.
Wu Q; Peng M; Lv C; Chen L; Mao X; Lin T; Sun P; Wang Y
Clin Transl Oncol; 2023 Apr; 25(4):1114-1123. PubMed ID: 36471225
[TBL] [Abstract][Full Text] [Related]
19. Martrilin-3 (MATN3) Overexpression in Gastric Adenocarcinoma and its Prognostic Significance.
Wu PL; He YF; Yao HH; Hu B
Med Sci Monit; 2018 Jan; 24():348-355. PubMed ID: 29343680
[TBL] [Abstract][Full Text] [Related]
20. Sineoculis homeobox homolog 1 protein as an independent biomarker for gastric adenocarcinoma.
Lv H; Cui A; Sun F; Zhang Y; Li Y; Li L; Lin Z
Exp Mol Pathol; 2014 Aug; 97(1):74-80. PubMed ID: 24866365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
